Citations

Clear

3942 citation(s) found for "To, Van".

Association of Serum Endocannabinoid Levels with Pancreatitis and Pancreatitis-Related Pain
Goodman, Marc T. , Lombardi, Christina , Torrens, Alexa , Saloman, Jami L. , Yang, Yunlong, Fisher, William E., Fogel, Evan L. , Forsmark, Christopher E. , Conwell, Darwin L. , Hart, Phil A. , Park, Walter G. , Topazian, Mark, Vege, Santhi Swaroop , Andersen, Dana K. , Yadav, Dhiraj , Goodman, Marc T , Vege, Santhi S, Saloman, Jami L , Bresee, Catherine J. , Li, Liang , Forsmark, Chris E. , Conwell, Darwin L. , Van Den Eeden, Stephen K , Bellin, Melena D. , Serrano, José , Pandol, Stephen J. , Piomelli, Daniele

Mayo Clinic

Cannabis & Cannabinoid Research | September 18, 2024 | Volume: 10 | Issue: 1 | Pages: 60-70

10.1089/can.2024.0079 | PMID 39291350 Get It

Background and Aims: This investigation examined the association of pancreatitis and pancreatitis-related pain with serum levels of two endocannabinoid molecules such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG) and two paracannabinoid molecules such as oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). Methods: A case–control study was conducted within the Prospective Evaluation of Chronic Pancreatitis for Epidemiological and Translational Studies, including participants with no pancreas disease ( N = 56), chronic abdominal pain of suspected pancreatic origin or indeterminate chronic pancreatitis (CP) ( N = 22), acute pancreatitis ( N = 33), recurrent acute pancreatitis ( N = 57), and definite CP ( N = 63). Results: Circulating AEA concentrations were higher in women than in men ( p = 0.0499), and PEA concentrations were higher in obese participants than those who were underweight/normal or overweight ( p = 0.003). Asymptomatic controls with no pancreatic disease had significantly ( p = 0.03) lower concentrations of AEA compared with all disease groups combined. The highest concentrations of AEA were observed in participants with acute pancreatitis, followed by those with recurrent acute pancreatitis, chronic abdominal pain/indeterminant CP, and definite CP. Participants with pancreatitis reporting abdominal pain in the past year had significantly ( p = 0.04) higher concentrations of AEA compared with asymptomatic controls. Levels of 2-AG were significantly lower ( p = 0.02) among participants reporting abdominal pain in the past week, and pain intensity was inversely associated with concentrations of 2-AG and OEA. Conclusions: Endocannabinoid levels may be associated with stage of pancreatitis, perhaps through activation of the CB1 receptor. Validation of our findings would support the investigation of novel therapeutics, including cannabinoid receptor-1 antagonists, in this patient population.
In memoriam: Ruud A.F. Krom, MD, PhD (1941–2024)
Berg, Aad P. van den , Guichelaar, Maureen M. J., Kootstra, G., Porte, Robert J. , Slooff, Maarten J. H., Wiesner, Russell H., Alwayn, Ian P J , Hoek, Bart van , Janssen, Harry L.A. , Meijer, Vincent Erwin de , Wiesner, Russell H.

Mayo Clinic

Liver Transplantation | September 17, 2024 | Volume: 30 | Issue: 12 | Pages: 1330-1331

10.1097/lvt.0000000000000443 Get It

Centromedian thalamic deep brain stimulation for idiopathic generalized epilepsy: Connectivity and target optimization
Park, Sihyeong , Permezel, Fiona , Agashe, Shruti , Osman, Gamaleldin , Simpson, Hugh D. , Miller, Kai J. , Gompel, Jamie J. Van , Starnes, Keith , Lundstrom, Brian N. , Worrell, Gregory A. , Gregg, Nicholas M. , Van Gompel, Jamie J , Worrell, Gregory A , Lundstrom, Brian Nils , Gregg, Nicholas M , Agashe, Shruti H , Starnes, Donnie Keith , Park, Sihyeong

Mayo Clinic

Epilepsia | September 14, 2024 | Volume: 65 | Issue: 11 | Pages: No page available

10.1111/epi.18122 | PMID 39276007 Get It

Abstract There are limited treatment options for individuals with drug‐resistant idiopathic generalized epilepsy (IGE). Small, limited case series suggest that centromedian thalamus deep brain stimulation (CM‐DBS) may be an effective treatment option. The optimal CM‐DBS target for IGE is underexamined. Here, we present a retrospective analysis of CM‐DBS targeting and efficacy for five patients with drug‐resistant IGE. Volume of tissue activated (VTA) overlap with CM nucleus was performed using an open‐source toolbox. Median follow‐up time was 13 months. Median convulsive seizure frequency reduction was 66%. One patient had only absence seizures, with >99% reduction in absence seizure frequency. Four patients had electrode contacts positioned within the CM nucleus target, all of whom had >50% reduction in primary semiology seizure, with 85% median seizure reduction ( p = .004, paired‐sample t test). Volumetric “sweet‐spot” mapping revealed that best outcomes were correlated with stimulation of the middle ventral CM nucleus. Connectivity strength between the sweet‐spot region and central peri‐Rolandic cortex was increased significantly relative to other cortical regions ( p = 8.6 × 10 −4 , Mann–Whitney U test). Our findings indicate that CM‐DBS can be an effective treatment for patients with IGE, highlight the importance of accurate targeting and targeting analysis, and within the context of prior work, suggest that ideal CM‐DBS targets may be syndrome specific.
The evolving role of the modern perfusionist: Insights from processed electro-encephalography
Bouchez, Stefaan , Gruenbaum, Benjamin F. , Vaerenbergh, Geert Van, Somer, Filip De , De Somer, Filip , Gruenbaum, Benjamin Fredrick

Mayo Clinic

Perfusion | September 12, 2024 | Volume: 40 | Issue: 5 | Pages: 1110-1123

10.1177/02676591241284864 | PMID 39263861 Get It

Introduction: Since its origin in the 1920s, electroencephalography (EEG) has become a viable option for anesthesia and perfusion teams to monitor anesthetic delivery, optimizing drug dosage and enhancing patient safety. Patients undergoing cardiopulmonary bypass (CPB) are at particular high risk for excessive or inadequate anesthetic doses. During CPB, traditional physiological indicators such as heart rate and blood pressure can be significantly altered. These abnormalities are compounded by rapid changes in anesthetic concentration from hemodilution, circuit absorption, and altered pharmacokinetics. Method: This narrative highlights the use of processed EEG with spectral analysis for anesthetic management during CPB. Conclusion: We emphasize that neuromonitoring using processed EEG during CPB can assess adequacy of anesthesia delivery and monitor for pathologic conditions that can compromise brain function such as inadequate cerebral blood flow, emboli, and seizures. This information is highly valuable for the clinical team including the perfusionist, who regularly diagnose and manage these pathological conditions.
Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment
Fernandez, Katharine , Hoetink, Alex E. , Berndtson, Deborah, Clark, Khaya D. , Dreisbach, Laura , Grosnik, Amy, Jamis, Carmen, Lee, John , Liberman, Patrícia Helena Pecora, Milnes, Trisha, Meijer, Annelot J. M. , Ortiz, Candice E., Rooker, Jennessa , Heuvel-Eibrink, Mary M. van den, Brewer, Carmen C. , Poling, Gayla L. , Clark, Khaya , Konrad‐Martin, Dawn , Geller, James I. , Goffi-Gómez, María Valéria Schmidt , Knight, Kristin R. , Lee, David S. , Sanchez, Victoria A , Heuvel‐Eibrink, Mary M. van den

Mayo Clinic

Ear & Hearing | September 12, 2024 | Volume: 46 | Issue: 2 | Pages: 286-297

10.1097/aud.0000000000001592 | PMID 39261989 Get It

Ototoxicity is among the adverse events related to cancer treatment that can have far-reaching consequences and negative impacts on quality-of-life for cancer patients and survivors of all ages. Ototoxicity management (OtoM) comprises the prevention, diagnosis, monitoring, and treatment, including rehabilitation and therapeutic intervention, of individuals who experience hearing loss, tinnitus, or balance/vestibular difficulties following exposures to ototoxic agents, including platinum chemotherapy (cisplatin, carboplatin) and cranial radiation. Despite the well-established physical, socioeconomic, and psychological consequences of hearing and balance dysfunction, there are no widely adopted standards for clinical management of cancer treatment-related ototoxicity. Consensus recommendations and a roadmap are needed to guide development of effective and feasible OtoM programs, direct research efforts, address the needs of caregivers and patients at all stages of cancer care and survivorship. Here we review current evidence and propose near-term to longer-term goals to advance OtoM in five strategic areas: (1) beneficiary awareness, empowerment, and engagement, (2) workforce enhancement, (3) program development, (4) policy, funding, and sustainability, and (5) research and evaluation. The goal is to identify needs and establish a roadmap to guide worldwide adoption of standardized OtoM for cancer treatment and improved outcomes for patients and survivors.
Decoded cardiopoietic cell secretome linkage to heart repair biosignature
Garmany, Armin , Arrell, D. Kent , Yamada, Satsuki , Jeon, Ryoung‐Hoon , Behfar, Atta , Park, Sungjo , Terzic, André , Jeon, Ryounghoon , Behfar, Atta , Terzic, Andre

Mayo Clinic

Stem Cells Translational Medicine | September 11, 2024 | Volume: 13 | Issue: 11 | Pages: 1144-1159

10.1093/stcltm/szae067 | PMID 39259666 Get It

Abstract Cardiopoiesis-primed human stem cells exert sustained benefit in treating heart failure despite limited retention following myocardial delivery. To assess potential paracrine contribution, the secretome of cardiopoiesis conditioned versus naïve human mesenchymal stromal cells was decoded by directed proteomics augmented with machine learning and systems interrogation. Cardiopoiesis doubled cellular protein output generating a distinct secretome that segregated the conditioned state. Altering the expression of 1035 secreted proteins, cardiopoiesis reshaped the secretome across functional classes. The resolved differential cardiopoietic secretome was enriched in mesoderm development and cardiac progenitor signaling processes, yielding a cardiovasculogenic profile bolstered by upregulated cardiogenic proteins. In tandem, cardiopoiesis enhanced the secretion of immunomodulatory proteins associated with cytokine signaling, leukocyte migration, and chemotaxis. Network analysis integrated the differential secretome within an interactome of 1745 molecules featuring prioritized regenerative processes. Secretome contribution to the repair signature of cardiopoietic cell-treated infarcted hearts was assessed in a murine coronary ligation model. Intramyocardial delivery of cardiopoietic cells improved the performance of failing hearts, with undirected proteomics revealing 50 myocardial proteins responsive to cell therapy. Pathway analysis linked the secretome to cardiac proteome remodeling, pinpointing 17 cardiopoiesis-upregulated secretome proteins directly upstream of 44% of the cell therapy-responsive cardiac proteome. Knockout, in silico, of this 22-protein secretome-dependent myocardial ensemble eliminated indices of the repair signature. Accordingly, in vivo, cell therapy rendered the secretome-dependent myocardial proteome of an infarcted heart indiscernible from healthy counterparts. Thus, the secretagogue effect of cardiopoiesis transforms the human stem cell secretome, endows regenerative competency, and upregulates candidate paracrine effectors of cell therapy-mediated molecular restitution.
Digital behaviour change intervention for weight loss maintenance in adults with obesity: a feasibility pilot study of eCHANGE
Asbjørnsen, Rikke Aune , Børøsund, Elin , Hjelmesæth, Jøran , Smedsrød, Mirjam Lien , Ollivier, M. , Wentzel, Jobke , Clark, Matthew M. , Gemert‐Pijnen, Julia E.W.C. van , Nes, Lise Solberg , Solberg Nes, Lise , Børøsund, Elin , Ollivier, M.

Mayo Clinic

Behaviour & Information Technology | September 10, 2024 | Volume: 44 | Issue: 11 | Pages: 2577-2595

10.1080/0144929x.2024.2399299 Get It

Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections
Boutzoukas, Angelique E , Mackow, Natalie , Giri, Abhigya, Komarow, Lauren , Hill, Carol , Chen, Liang , Doi, Yohei , Satlin, Michael J. , Arias, César A. , Wang, Minggui , Moreo, Laura Mora , Herc, Erica , Cober, Eric , Weston, Gregory , Fowler, Vance G. , Pettigrew, Melinda M. , Jabbour, Jean-Francois , Reyes, Jinnethe , Munita, José M. , Valderrama, Sandra , Patel, Robin , van Duin, David , Chen, Liang , Doi, Yohei , Pettigrew, M M , Evans, Scott R , Wang, Minggui , Reyes, Jinnethe , Munita, Jose M , Arias, César A. , Weston, Gregory , Patel, Robin , Bonomo, Robert A. , Fowler, Vance G.

Mayo Clinic

Journal of Antimicrobial Chemotherapy | September 5, 2024 | Volume: 79 | Issue: 11 | Pages: 2916-2922

10.1093/jac/dkae306 | PMID 39236214 Get It

Abstract Background The CDC reported a 35% increase in hospital-onset (HO) carbapenem-resistant Enterobacterales (CRE) infections during the COVID-19 pandemic. We evaluated patient outcomes following HO and community-onset (CO) CRE bloodstream infections (BSI). Methods Patients prospectively enrolled in CRACKLE-2 from 56 hospitals in 10 countries between 30 April 2016 and 30 November 2019 with a CRE BSI were eligible. Infections were defined as CO or HO by CDC guidelines, and clinical characteristics and outcomes were compared. The primary outcome was desirability of outcome ranking (DOOR) 30 days after index culture. Difference in 30-day mortality was calculated with 95% CI. Results Among 891 patients with CRE BSI, 65% were HO (582/891). Compared to those with CO CRE, patients with HO CRE were younger [median 60 (Q1 42, Q3 70) years versus 65 (52, 74); P < 0.001], had fewer comorbidities [median Charlson comorbidity index 2 (1, 4) versus 3 (1, 5); P = 0.002] and were more acutely ill (Pitt bacteraemia score ≥4: 47% versus 32%; P < 0.001). The probability of a better DOOR outcome in a randomly selected patient with CO BSI compared to a patient with HO BSI was 60.6% (95% CI: 56.8%–64.3%). Mortality at 30-days was 12% higher in HO BSI (192/582; 33%) than CO BSI [66/309 (21%); P < 0.001]. Conclusion We found a disproportionately greater impact on patient outcomes with HO compared to CO CRE BSIs; thus, the recently reported increases in HO CRE infections by CDC requires rigorous surveillance and infection prevention methods to prevent added mortality.
Multiligament knee injury (MLKI): an expert consensus statement on nomenclature, diagnosis, treatment and rehabilitation
Murray, Iain R. , Makaram, Navnit S. , Moatshe, Gilbert , Crossley, Kay M. , Davis, Aileen M. , Tuca, María , Eun, SeungPyo, Noyes, Frank R. , Marx, Robert G. , Harner, Chris, Levy, Bruce A. , Whelan, Daniel B. , Hatch, George F. Rick , Wahl, Christopher J. , Thorborg, Kristian , Irrgang, James J. , MacDonald, Peter , Shelbourne, K. Donald , Musahl, Volker , Miller, Mark D., LaPrade, Robert F. , Murray, Iain Robert , Moatshe, Gilbert , Crossley, Kay , Davis, Aileen , Janse van Rensburg, Dina C , Emery, Carolyn A , King, Enda , Engebretsen, Lars , Seil, Romain , Verhagen, Evert , Irrgang, James J , LaPrade, Robert F , Geeslin, Andrew G. , Chahla, Jorge , Kew, Michelle Elizabeth , Potter, Hollis G. , Emery, Carolyn A. , Eun, Seung-Pyo, Grindem, Hege , Cook, James L. , Pujol, Nicolas , Medvecky, Michael J. , Stuart, Michael J. , Krych, Aaron J. , Engebretsen, Lars , Stannard, James P. , Seil, Romain , Fanelli, Gregory C. , Maak, Travis G. , Verhagen, Evert , Hirschmann, Michael T. , Schenck, Robert C.

Mayo Clinic

British Journal of Sports Medicine | September 5, 2024 | Volume: 58 | Issue: 23 | Pages: 1385-1400

10.1136/bjsports-2024-108089 | PMID 39237264 Get It

Multiligament knee injuries (MLKIs) represent a broad spectrum of pathology with potentially devastating consequences. Currently, disagreement in the terminology, diagnosis and treatment of these injuries limits clinical care and research. This study aimed to develop consensus on the nomenclature, diagnosis, treatment and rehabilitation strategies for patients with MLKI, while identifying important research priorities for further study. An international consensus process was conducted using validated Delphi methodology in line with British Journal of Sports Medicine guidelines. A multidisciplinary panel of 39 members from 14 countries, completed 3 rounds of online surveys exploring aspects of nomenclature, diagnosis, treatment, rehabilitation and future research priorities. Levels of agreement (LoA) with each statement were rated anonymously on a 5-point Likert scale, with experts encouraged to suggest modifications or additional statements. LoA for consensus in the final round were defined ‘a priori’ if >75% of respondents agreed and fewer than 10% disagreed, and dissenting viewpoints were recorded and discussed. After three Delphi rounds, 50 items (92.6%) reached consensus. Key statements that reached consensus within nomenclature included a clear definition for MLKI (LoA 97.4%) and the need for an updated MLKI classification system that classifies injury mechanism, extent of non-ligamentous structures injured and the presence or absence of dislocation. Within diagnosis, consensus was reached that there should be a low threshold for assessment with CT angiography for MLKI within a high-energy context and for certain injury patterns including bicruciate and PLC injuries (LoA 89.7%). The value of stress radiography or intraoperative fluoroscopy also reached consensus (LoA 89.7%). Within treatment, it was generally agreed that existing literature generally favours operative management of MLKI, particularly for young patients (LoA 100%), and that single-stage surgery should be performed whenever possible (LoA 92.3%). This consensus statement will facilitate clinical communication in MLKI, the care of these patients and future research within MLKI.
Beta-Blocker Use and Outcomes in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fraction
Henderson, Alasdair D , Shen, Li , Campbell, Ross T. , Boer, Rudolf A. de , Lam, Carolyn S.P., Maggioni, Aldo P. , Martínez, Felipe A. , Redfield, Margaret M. , Rouleau, Jean L. , Veldhuisen, Dirk Jan van, Zannad, Faı̈ez , Solomon, Scott, de Boer, Rudolf A , Maggioni, Aldo P , Matsumoto, Shingo , Kondo, Toru , Yang, Mingming , Anand, Inder S. , Desai, Akshay S , Lam, Carolyn S.P. , Packer, Milton , Veldhuisen, Dirk J. van , Vaduganathan, Muthiah , Zile, Michael R. , Jhund, Pardeep S. , McMurray, John J.V.

Mayo Clinic

European Journal of Heart Failure | August 31, 2024 | Volume: 27 | Issue: 1 | Pages: 124-139

10.1002/ejhf.3383 | PMID 39215677 Get It

ABSTRACT Aims In the absence of randomized trial evidence, we performed a large observational analysis of the association between beta-blocker (BB) use and clinical outcomes in patients with heart failure (HF) and mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF). Methods and results We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER). The primary outcome was the composite of cardiovascular death or HF hospitalization. Among the 16 951 patients included, the mean left ventricular ejection fraction (LVEF) was 56.8%, and 13 400 (79.1%) had HFpEF (LVEF ≥50%). Overall, 12 812 patients (75.6%) received a BB. The median bisoprolol-equivalent dose of BB was 5.0 (Q1–Q3: 2.5–5.0) mg with BB continuation rates of 93.1% at 2 years (in survivors). The unadjusted hazard ratio (HR) for the primary outcome did not differ between BB users and non-users (HR 0.98, 95% confidence interval [CI] 0.91–1.05), but the adjusted HR was lower in BB users than non-users (0.81, 95% CI 0.74–0.88), and this association was maintained across LVEF (pinteraction = 0.88). In subgroup analyses, the adjusted risk of the primary outcome was similar in BB users and non-users with or without a history of myocardial infarction, hypertension, or a baseline heart rate <70 bpm. By contrast, a better outcome with BB use was seen in patients with atrial fibrillation compared to those without atrial fibrillation (pintreraction = 0.02). Conclusions In this observational analysis of non-randomized BB treatment, there was no suggestion that BB use was associated with worse HF outcomes in HFmrEF/HFpEF, even after extensive adjustment for other prognostic variables.